&w=3840&q=100)
Newgen Software stock falls 6% after muted Q1 performance; check details
At 1 PM, the stock was quoting at ₹1,043, down 4.43 per cent from the previous day's close of ₹1,091.4. In comparison, the benchmark NSE Nifty50 index was trading at 25,178.4 levels, down 33.35 points or 0.13 per cent. The company's total market capitalisation stood at ₹14,771.51 crore. The stock has plunged nearly 43 per cent from its 52-week high of ₹1,798.9 touched on January 15, 2025.
Newgen Software Q1FY26 results
In the June 2025 quarter, the company reported a revenue from operations of ₹320.65 crore, down 25 per cent from ₹429.88 crore in the previous quarter ended March 31, 2025 (Q4FY25). The company's net profit for the period fell 54 per cent to ₹49.72 crore compared to ₹108.33 crore in the previous quarter.
Newgen's revenue from the European business slipped to ₹103.4 crore from ₹138.56 crore in the March quarter. APAC revenue fell 29.6 per cent to ₹49.2 crore from ₹69.9 crore in the previous quarter.
On a yearly basis, the company's performance remained muted with marginal growth overall. Revenue from operations rose 1.8 per cent from ₹314.7 crore in the year-ago period. Net profit increased 4.4 per cent compared to ₹47.56 crore in the June 2024 quarter. The company's earnings before interest, tax, depreciation and amortisation (Ebitda) declined 6 per cent to ₹45 crore. Ebitda margins narrowed to 14 per cent to 15 per cent from the year-ago period.
About Newgen Software
Incorporated in 1992, Newgen Software Technologies specialises in software product development, offering end-to-end solutions that span workflow automation, document management, and imaging. The company's solutions enable document-intensive organisations such as finance and banking, insurance and government departments. It serves business-to-business (B2B) customers across various sectors, including banking, financial services, government, shared services, healthcare, insurance, telecom, and more. It has a presence in around 76 countries, including India, the USA, Canada, UAE, Saudi Arabia, the UK, the Philippines, Indonesia, Singapore, and Australia.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Clean Science shares tank 7% post Q1 results; should you buy, sell or hold?
Clean Science share price today: Shares of chemical manufacturer Clean Science & Technology crashed over 7 per cent to hit an intra-day low of ₹1,332.4 on the NSE after it reported its June 2025 quarter (Q1FY26) results. At 11:45 AM, the stock was trading 7.4 per cent lower at ₹1,338 compared to the previous day's close of ₹1,445.2 on the NSE. In comparison, the benchmark NSE Nifty 50 index was trading at 24,953.90 levels, down by 157.55 points or 0.63 per cent. The company's total market capitalisation stood at ₹14,271.69 crore. The stock has plunged over 21 per cent from its 52-week high of ₹1,690 touched on August 1, 2024. Clean Science & Technology Q1FY26 result update Clean Science's consolidated revenue from operations for the June 2025 quarter came in at ₹242.86 crore, up 8.4 per cent year-on-year (Y-o-Y) from ₹224 crore in the year-ago period. The company reported a 6.2 per cent Y-o-Y increase in profit after tax (PAT) to ₹70 crore against ₹65.9 crore in the June 2024 quarter. Its earnings before interest, tax, depreciation and amortisation (Ebitda) stood at ₹100 crore, up 5 per cent Y-o-Y from ₹95 crore in the year-ago period. Ebitda margin slipped to 41.7 per cent from 42.8 per cent. During the earnings call, the management highlighted that the promoters are evaluating the possibility of selling a minority stake to support the family estate planning. Currently, the promoters own a 74.97 per cent stake in the company. Brokerage views on Clean Science & Technology: JM Financial According to analysts at JM Financial, Clean Science's Q1 Ebitda was in line with their estimates. "We expect the subsidiary to start contributing positively from Q3FY26, driven by the ramp-up of value-added HALS grades. Besides HALS, the company's two new performance chemical capacities are on track to be commercialised, with one set to see commercial production in September 2025 and the other in Q4FY26, the brokerage said in a note. The brokerage has maintained a 'Buy' with a revised September 2026 TP of ₹1,780 per share (from ₹1,820 earlier), based on 40x Sep'27E EPS. Motilal Oswal Financial Services (MOFSL) "While the non-established products face demand softness, we expect the established products, which contribute to 83 per cent of standalone sales, to continue to deliver steady growth, coupled with the commissioning of Performance Chemical 1 in Q2FY26 and Performance Chemical 2 by Q4FY26, are expected to be an additional revenue driver," the brokerage said. MOFSL has lowered its estimates for FY26/FY27 cuts by 9 per cent each, owing to higher tax rates and expects a revenue/ Ebitda/ PAT CAGR of 23/23/27 per cent during FY25-27E. The brokerage has maintained a 'Neutral' rating with a target price of ₹1,350. About Clean Science & Technology Incorporated in 2003, Clean Science and Technology is engaged in the manufacturing of performance chemicals, pharma and agrochemicals, and FMCG chemicals. The company is involved in B2B business and its products find applications in various critical end-user industries and everyday product verticals, including precursors for agricultural chemicals, antioxidants for food and infant food formulations, precursors to manufacture APIs for cough syrup, polymers and monomers, the cosmetic industry, perfumes, and many other applications. Clean Science serves both national and international clients, including institutions, distributors, and dealers. It has a presence in 16 states in India and 36 countries worldwide.
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Newgen Software shares slip 6% post Q1; opportunity or exit signal?
Newgen Software Technologies shares slipped 5.7 per cent after the company released its Q1 results. The stock logged an intraday low at ₹967.3 per share on BSE. At 11:27 AM, Newgen Software Technologies share price was trading 5.52 per cent lower at ₹969.8 per share on the BSE. In comparison, the BSE Sensex was down 0.59 per cent at 81,777.81. The company's market capitalisation stood at ₹13,734.81 crore. The 52-week high of the stock was at ₹1,795.5 per share, and the 52-week low of the stock was at ₹740.05 per share. Newgen Software Technologies Q1 results The company on Thursday, after market hours, reported a net profit of ₹49.7 crore for Q1FY26, up 4.5 per cent, from ₹47.6 crore a year ago. However, sequentially, the net profit declined 54 per cent from ₹108 crore in Q4. The company's revenue from operations increased 1.9 per cent to ₹320.6 crore as compared to ₹314.7 crore a year ago and ₹429.89 crore in Q4. Should you buy or sell Newgen Software Technologies shares? ICICI Securities has maintained a 'Reduce' rating on the stock and has cut the target to ₹970 per share from ₹1,020. Newgen reported a sharp miss against ICICI Securities estimates on revenue, with growth of 1.9 per cent Y-o-Y – much lower than the company's aspiration of 20 per cent year-on-year (Y-o-Y) growth. Revenue was impacted by lower large-license deals across its key vertical of banking (-5.2 per cent Y-o-Y) and key markets of India (3 per cent Y-o-Y) and the Middle East (0.3 per cent Y-o-Y). Demand was impacted by macro headwinds in the Middle East and a pull-back in retail lending in India. The brokerage has cut earnings per share (EPS) estimates by 4-5 per cent led by a cut in revenue estimates. We model 7 per cent/17 per cent/15 per cent revenue growth in Rupee terms in FY26/27/28. About Newgen Software Newgen is the leading provider of a unified digital transformation platform with native process automation, content services, and communication management capabilities. Globally, enterprises rely on Newgen's industry-recognised low-code application platform to develop and deploy complex, content-driven, and customer-engaging business applications on the cloud. From onboarding to service requests, lending to underwriting, and for many more use cases across industries. Newgen unlocks simple with speed and agility.
&w=3840&q=100)
Business Standard
26 minutes ago
- Business Standard
Anthem Biosciences IPO to list on July 21: Here's what latest GMP hints at
Anthem Biosciences IPO listing forecast: As investors await the debut of Anthem Biosciences shares on the bourses, the grey market premium (GMP) indicates a favourable listing for the company's shares on the BSE and NSE, scheduled for Monday, July 21, 2025. Ahead of the listing, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹713 per share, reflecting a grey market premium (GMP) of ₹143 per share or nearly 25.09 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities. Should the current grey market trends sustain, Anthem Biosciences shares may list on the BSE and NSE at around ₹713 (issue price + GMP). Thus, investors who have been allotted Anthem Biosciences shares can expect a gain of over 25 per cent per share upon listing. That said, since the GMP is an unregulated and unofficial indicator, investors should not consider it a reliable measure of the company's actual market performance. Anthem Biosciences IPO details The public offering of Anthem Biosciences, estimated at ₹3,395 crore, comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares. Anthem Biosciences IPO was available for subscription from July 14, 2025 till July 16, 2025. Offered at a price band of ₹540–570 with a lot size of 26 shares, it received strong demand from investors, getting oversubscribed by 63.86 times, riding on the back of qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data. In its RHP papers, Anthem Biosciences mentioned that it will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS. About Anthem Biosciences Anthem Biosciences (ABL) is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO). With fully integrated operations spanning drug discovery, development, and manufacturing, the company helps drug companies develop and produce medicines. It works with a wide range of global clients, from small biotech firms to big pharma companies, across 44 countries including the US., Europe, and Japan.
